PuraMed BioScience engages in the research, development, and
marketing of non-prescription medicinal and healthcare products.
In addition to LipiGesic M, PuraMed BioScience plans to
launch LipiGesic H for tension-type headaches as well as LipiGesic
PM, which provides a remedy for insomnia and other sleep
disorders. For more information visit www.puramedbioscience.com
PMBSD Nears Development of
Cannabis Medication for Treatment of Epilepsy
Last Updated: Oct.
10, 2014 - 11:00am EST
(NEW YORK)--PuraMed BioScience, Inc. (OTC:PMBSD),
and developer of over-the-counter health and wellness products,
announced it is nearing completion of a CBD cannabis rich
medication for the treatment of epilepsy.
The Company is developing an over the counter medication, using
cannabis hemp oil (CBD) for the treatment of Epilepsy. Recent
studies have shown CBD to be extremely effective in the treatment
of epilepsy, and with PBMSD already having a natural over the
counter migraine product, MigraPure, the combination of both could
yield a medication with wide ranging benefits to suffers of epilepsy,
and chronic migraines.
PMBSD already has distribution relationships with such large big
box chains, such as Walgreens, and CVS, so developing a product
from production to store shelves could be much easier compared to
new over the counter developers.
As of Oct. 7, 2014, the Company has around 40
million common shares issued and outstanding, given PMBSD a
market cap of around $200,000 to $400,000.
Safe Harbor Statements:
investor presentation may include statements that may constitute
forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Although the Company believes that the expectations
reflected in such forward-looking statements are based on
reasonable assumptions, such statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected.
This is NOT a solicitation to Buy or Sell any security, but rather
is for informational purposes only. Content contained herein
includes facts, views, opinions and recommendations of individuals
and organizations deemed of interest. Wall Street Newscast
("WSNC") does not guarantee the accuracy, completeness
or timeliness of, or otherwise endorse these views, opinions or
recommendations, or give investment advice. WSNC, its affiliates,
or directors, may or may not hold a position in the above security
from time to time, and investors are encourage to consider this as
a possible conflict of interest when reviewing this information.
In Compliance with SEC Rule 17B Wall Street Newscast was
compensated one thousand dollars for research and media
WSNC may hold a position in above securities from time to time,
and thus should be considered a possible conflict of interest when
reviewing this report and information. These investments may
involve a high degree of risk, thus investors are highly
encouraged to consult with a financial advisor before any and all